Marinomed Biotech to Launch Carragelose Eye Drops in Europe in 2024

Marinomed Biotech announced it plans to introduce a new Carragelose eye drop product (MAM-1001-3) with an expected market launch in Austria targeted for the first half of 2024. Marinomed said it has started a business development process to identify partners for the marketing of the product in other global markets.

Carragelose is a sulfated polymer from red seaweed and a broadly active virus-blocking compound. It is known as a gentle, effective, and safe prevention and treatment of various viral respiratory infections, according to Marinomed. Clinical and preclinical studies have shown that Carragelose forms a protective layer on the mucosa that prevents viruses from infecting cells. Laboratory and clinical data have demonstrated that Carragelose can also inhibit the spreading of SARS-CoV-2. [1,2]

“The introduction of Carragelose eye drops is a logical addition to our current OTC portfolio. This asset has an upright certification and is ready for partnering and marketing, thus will be generating revenues in the near to medium term,” Andreas Grassauer, CEO of Marinomed, said in a company news release. “The product is intended to provide relief for dry eyes. Carragelose has excellent moisturizing properties and an outstanding safety profile. In addition, Carragelose is well known for its virus-blocking effectiveness.”

Marinomed is the holder of the IP rights and has licensed Carragelose for marketing in Europe, North America, Australia, and parts of Asia and Latin America.